A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE SAFETY, EFFICACY AND PHARMACODYNAMICS OF TEV 53275 ADMINISTERED SUBCUTANEOUSLY IN ADULT PATIENTS WITH PERSISTENT EOSINOPHILIC ASTHMA

Registry ID
TV53275 AS 20033
Source registry
HEALTH_CANADA
Status
Closed
Phase
PHASE2
Study type
INTERVENTIONAL
Sponsor
TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D INC
Start date
2022-02-22
Completion date
2022-03-24
Last update
2021-03-19

Conditions

Related clinical trials

View on source registry